Palvella Therapeutics (NASDAQ:PVLA) Given Average Recommendation of “Buy” by Analysts

Palvella Therapeutics (NASDAQ:PVLA) has been given a consensus rating of “Buy” by the eight ratings firms that are currently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $44.43.

PVLA has been the subject of several research analyst reports. Jones Trading assumed coverage on shares of Palvella Therapeutics in a research report on Tuesday, March 25th. They set a “buy” rating and a $45.00 price objective for the company. Stifel Nicolaus started coverage on Palvella Therapeutics in a research report on Wednesday, March 26th. They issued a “buy” rating and a $45.00 target price on the stock. TD Cowen initiated coverage on shares of Palvella Therapeutics in a report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 target price for the company. Scotiabank assumed coverage on shares of Palvella Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price target on the stock. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $39.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, February 26th.

Insider Transactions at Palvella Therapeutics

In related news, Director George M. Jenkins bought 2,500 shares of the business’s stock in a transaction on Wednesday, April 9th. The shares were purchased at an average cost of $20.13 per share, with a total value of $50,325.00. Following the acquisition, the director now owns 183,171 shares of the company’s stock, valued at $3,687,232.23. This represents a 1.38 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.39% of the stock is owned by company insiders.

Hedge Funds Weigh In On Palvella Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC acquired a new position in shares of Palvella Therapeutics in the 4th quarter worth approximately $125,000. Toronto Dominion Bank acquired a new position in Palvella Therapeutics in the fourth quarter valued at $159,000. Geode Capital Management LLC bought a new stake in Palvella Therapeutics during the fourth quarter valued at $171,000. Cresset Asset Management LLC acquired a new stake in Palvella Therapeutics during the 4th quarter worth about $251,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Palvella Therapeutics in the 4th quarter valued at about $256,000. 40.11% of the stock is currently owned by institutional investors.

Palvella Therapeutics Trading Down 0.2 %

PVLA stock opened at $24.36 on Friday. The firm has a 50-day moving average price of $23.45. The company has a market cap of $268.42 million, a price-to-earnings ratio of -2.01 and a beta of 0.10. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $29.27.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.